<DOC>
	<DOCNO>NCT01619085</DOCNO>
	<brief_summary>The aim extension trial assess long-term safety BIBF 1120 treatment patient Idiopathic Pulmonary Fibrosis complete one year treatment follow period double-blind phase III placebo control parent trial ( 1199.32 1199.34 ) , wish continue treatment BIBF 1120 .</brief_summary>
	<brief_title>Extension Trial Long Term Safety BIBF 1120 Patients With Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : 1 . Signed Informed Consent consistent International Conference HarmonisationGood Clinical Practices ( ICHGCP ) local law prior trial participation . 2 . Patients trial 1199.32 1199.34 complete 52 week treatment period perform followup visit . Exclusion criterion : 1 . Aspartate aminotransferase ( AST ) , Alanine aminotransferase ( ALT ) &gt; 1.5 fold Upper Limit Normal ( ULN ) ( Patients complete parent trial transaminase value &gt; 1.5 fold ULN &lt; 3 fold ULN consider eligible ) 2 . Bilirubin &gt; 1.5 fold ULN 3 . Bleeding risk 4 . Planned major surgery within next 3 month , include lung transplantation , major abdominal major intestinal surgery . 5 . New major thromboembolic event develop completion parent trial . 6 . Time period &gt; 12 week Visit 9 parent trial Visit 2 study . 7 . Usage investigational drug completion parent trial plan usage specific investigational drug course trial . 8 . A disease condition opinion investigator may put patient risk participation trial limit patient ' ability participate trial . 9 . Alcohol drug abuse opinion investigator would interfere trial participation . 10 . Pregnant woman woman breast feed child bear potential use two effective method birth control ( one barrier one highly effective nonbarrier ) least 1 month prior Visit 2 and/or commit use 3 month end treatment .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>